Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of ALA-101 and opened its first trial site at The Alfred Hospital in Melbourne.
The ASX-listed company said the batch has cleared the standards required for dosing in a first-in-human study, and that ethics and governance approvals at The Alfred have now been finalised. With a site open and product in hand, screening and patient enrolment can begin, and Arovella expects to dose its first patient later this month.
The company describes ALA-101 as an 'off-the-shelf' cell therapy, built from healthy donor cells in batches rather than custom-made from each patient's own blood. Arovella argues this approach could allow treatment to reach patients faster and at lower cost than conventional therapies, which typically require harvesting and processing a patient's own cells before reinfusion.
Arovella's Acting Chief Executive Officer, Dr Nicole van der Weerden, called the batch release a milestone that proves the platform works beyond the laboratory. She said manufacturing the product to clinical standard while meeting requirements set by the US Food and Drug Administration demonstrates that the company can produce a therapy ready for real patients, and that attention now shifts to screening and enrolling the first participant at The Alfred.
Chairman David Williams said activating the first site and releasing the first batch mark the shift from laboratory research to actual patient treatment. He emphasised that the ability to manufacture cells in bulk without depending on individual patients' own cells is central to Arovella's pitch, one built on the promise of a therapy that is cheaper, faster to produce and available closer to when patients need it.
The therapy itself relies on invariant natural killer T cells, a platform Arovella licensed from Imperial College London, engineered to fight blood cancers, solid tumours and autoimmune disease. ALA-101 combines a chimeric antigen receptor targeting the CD19 antigen found on many cancer cells with the invariant T cell receptor naturally present in these immune cells, which recognises a separate cancer-associated antigen called CD1d. The therapy has already had its Investigational New Drug application accepted by the FDA and is classified as allogeneic, meaning it can be transferred from a healthy donor into a patient rather than requiring cells sourced from the patient themselves.
